Table 3. Patients and controls sub grouped according to age and gender. Shown are percentages of individuals per group as well as the TCF-4 (TCF7L2) rs3814570 T- allele frequency (minor allele frequency MAF). Differences in genotype distribution compared to controls in general as well as the amount of all carriers (allele positivity) and the amount of homozygous carriers were subject to t- tests in patients with ileal CD. Finally, results of the Armitage's trend tests for verification of significant associations of the rare T- variant are shown.

Age and gender
overall		controls*	L1	L2	L3	ileal CD	CD		controls <> L1+L3
Age groups	A1 (<16 Y)	2,42%	5,88%	6,02%	9,76%	8,64%	8,06%	statistics for A3	C<>T	CC<>CT+TT
	MAF	34,85%	26,92%	23,08%	23,58%	24,24%	24,05%		1.37; p = 0.06312	1.32; p = 0.20576
	A2(16–40 y)	58,22%	72,85%	68,06%	80,85%	78,53%	76,22%		Armitage's trend	CC<>TT
	MAF	25,28%	31,06%	24,15%	29,61%	30,00%	28,85%		1.37; p = 0.07315	2.02; p = 0.04347
	A3(>40 y)	39,35%	21,27%	25,93%	9,39%	12,83%	15,71%	statistics for A2	C<>T	CC<>CT+TT
	MAF	25,28%	27,66%	23,21%	35,29%	31,63%	28,57%		1.27; p = 0.00567	1.36; p = 0.00438
gender	male/M	58,21%	50,88%	35,11%	40,43%	43,46%	41,59%		Armitage's trend	CC<>TT
	MAF	25,63%	33,91%	20,89%	28,57%	30,38%	28,59%		1.22; p = 0.00818	1.39; p = 0.08396
	female/V	41,79%	49,12%	64,89%	59,57%	56,54%	58,41%
	MAF	25,44%	26,13%	26,71%	30,15%	29,14%	28,53%

MAF = minor allele frequency.

^*controls A1 only from Leuven.